An estimated 25 million Americans suffer from Asthma, but current medications such as inhalers have been deemed ineffective for 10-20% of its users. Regneron (REGN) and Sanofi (SAN) have partnered to crease a new Asthma drug, Dupilumab.
The fibroblast cell is known to play key roles in extracellular matrix synthesis, production of collagen, and production of growth factors all of which support the skin, soft tissues, and aid in wound healing. Fibrocell Science (FCSC) is an autologous cell therapy company whose sole focus is the development of aesthetic, medical, and scientific application that involve the use of the fibroblast cell.
Oxygen is one of the main elements vital to human survival. Oxygen Biotherapeutics’ (OXBT) mission is to research, develop, and market oxygen related products based on perflurocarbons technology. The team is driven to aid the human body in maintaining adequate oxygen levels to prevent disease and damage to tissues if oxygen flow were ever to be interrupted or inhibited.
On April 2nd, 2013, U.S. President Barack Obama unveiled the “BRAIN” Initiative, which is short for Brain Research through Advancing Innovative Neurotechnologies. The BRAIN Initiative may be known as the spiritual successor to the Human Genome Project, not only for its desire to understand a mysterious place known to medical science, but for taking its cues from the initial success of the HGP.
Bioinformatics is the field of science involved with using computational methods to convert raw biological data into meaningful biological paradigms. Part I of this article will discuss how bioinformatics data is generated. It will focus on the methods used to collect this data, and the companies that support this collection.
Editor’s Note: The following comes to us from media affiliate marcus evans. JC Scott, a speaker at the marcus evans Medical Device Manufacturing Summit Spring […]
Hard to believe we are just a few weeks away from OneMedForumNY 2013, June 26-27 in New York City. We’re excited to host a group […]
ISTO Technologies has a unique pipeline that has demonstrated both clinical progress and market success. With one commercialized product — a bone graft extender and substitute — and two late-stage clinical programs focusing in engineering cartilage tissue for knee and back, respectively, the company is poised to capture an opportunistic yet untapped market. OneMedRadio spoke with CFO Scott Gill about market opportunity, and finding success in a notoriously unfriendly space.
Actium Cancer Treatment (ACT) platform’s controlled heat (hyperthermia) has the potential to substantially increase the efficacy of chemotherapy and radiation First application: non-muscle-invasive bladder cancer (NMIBC).
Atossa Genetics believes it can prevent breast cancer by 2020 — and in the meantime, capture a unique market opportunity — with their novel cellular and molecular diagnostic risk assessment products for early detection. Yet in a burgeoning diagnostics space, and rapid advancement in cancer therapeutics, will this company find a niche?
Copyright © 2024 | WordPress Theme by MH Themes